| Literature DB >> 16956561 |
Guillermo Guhl1, Ana González-de Arriba, Esteban Daudén.
Abstract
Epidermal growth factor receptor (EGFR) inhibitors are a new group of drugs used in the treatment of several malignancies. Three molecules are approved at the moment: gefitinib and erlotinib for the treatment of non-small-cell lung cancer, and cetuximab for colorectal cancer. These drugs originate cutaneous side effects with a high frequency: acneiform rashes, paronychia and generalized xerodermia. In this paper we review these common side effects and how to manage them.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16956561 DOI: 10.1016/s0001-7310(06)73407-x
Source DB: PubMed Journal: Actas Dermosifiliogr ISSN: 0001-7310